Current recommendations for prostate-specific antigen testing are reviewed, as well as the initial results of two randomized trials. The potential risks of screening, including morbidity from overdiagnosis and overtreatment, are described.
No takes yet. Share an insight, caveat, or question.
Richard M. Hoffman (2011) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: